Efficacy and safety of Semaglutide in the treatment of type 2 diabetes mellitus patients with chronic heart failure and renal insufficiency
Objective To explore the clinical efficacy and safety of Semaglutide in type 2 diabetes mellitus(T2DM)patients with chronic heart failure(CHF)and renal insufficiency.Methods 71 patients with T2DM complicated with CHF and renal insufficiency admitted to the First Affiliated Hospital of Xinjiang Medical University from January 2022 to September 2022 were selected.According to the treatment scheme,the patients enrolled were randomly divided into the control group(insulin treatment,35 patients)and the treatment group(insulin combined with Semaglutide for treatment,36 patients).The clinical efficacy and safety of treatment were compared between two groups.Results After 3 months of treatment,the effective rate of HbAlc reaching the therapy standard in the treatment group(72.2％)was significantly higher than that in the control group(31.4％)(P＜0.05).After treatment,the body mass,and the levels of fasting blood glucose(FBG),glycosylated hemoglobin(HbAlc)and triglyceride(TG)in the treatment group showed the significant decrease and were significantly lower than those in the control group(P＜0.05).Compared with the control group,the combined use of Semaglutide treatment in the treatment group resulted in the increase in left ventricular ejection fractions(LVEF),and the decrease in brain natriuretic peptide(BNP)level,urinary albumin creatinine ratio(UACR)and urine α1-microglobulin(α1MG)level,and there were statistically significant differences in these indicators between two groups(P＜0.05).However,there was no significant difference in the adverse reactions between two groups(P＞0.05).Conclusion Semaglutide has a good blood glucose control effect on T2DM patients with CHF and renal insufficiency,can significantly improve cardiac function,reduce the progression of kidney disease,and has high clinical safety.
type 2 diabetes mellitusSemaglutidechronic heart failurerenal insufficiencyefficacy and safety
万方数据
维普
